Stay updated on Pembrolizumab+Cabozantinib in Head & Neck Squamous Cell Cancer Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab+Cabozantinib in Head & Neck Squamous Cell Cancer Clinical Trial page.

Latest updates to the Pembrolizumab+Cabozantinib in Head & Neck Squamous Cell Cancer Clinical Trial page
- Check7 days agoNo Change Detected
- Check14 days agoChange DetectedThe web page has been updated from version 2.16.11 to version 2.16.12.SummaryDifference0.1%
- Check21 days agoChange DetectedThe web page has been updated from version 2.16.10 to version 2.16.11.SummaryDifference0.1%
- Check29 days agoChange DetectedThe page has been updated to version v2.16.10, and the previous service alert regarding planned maintenance has been removed.SummaryDifference0.9%
- Check36 days agoChange DetectedThe webpage has updated its results reporting dates and added detailed criteria for evaluating adverse events related to study treatment, while removing previous references to serious adverse events and specific submission dates.SummaryDifference8%
- Check43 days agoChange DetectedThe web page has been updated to reflect a planned maintenance alert starting July 25th, during which most services will be unavailable for over 24 hours. Additionally, the version has been updated from v2.16.5 to v2.16.6.SummaryDifference0.9%
- Check57 days agoChange DetectedThe page has been updated to reflect a new version (v2.16.5) and indicates that results have been submitted, while previous information about the modernization of ClinicalTrials.gov data ingest and the absence of posted results has been removed.SummaryDifference1%
Stay in the know with updates to Pembrolizumab+Cabozantinib in Head & Neck Squamous Cell Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab+Cabozantinib in Head & Neck Squamous Cell Cancer Clinical Trial page.